



## Nationally Recognized Cardiology Practice Places Multiunit Order of the Acarix CADScor System

**Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that Connected Cardiovascular Care Associates (C3), the first U.S. cardiology practice dedicated exclusively to the digital monitoring of cardiac conditions, has placed a four-unit order of the CADScor System.**

The CADScor System will complement C3's suite of digital wearable devices, including smartwatches, digital blood pressure monitors, and weight scales, solidifying the practice's commitment to innovative, patient-centric care. This approach allows for continuous monitoring and early intervention, crucial for managing conditions such as heart blockages, rhythm problems, weakened heart function, and vascular issues like leg blockages or vein problems.

"We are pleased to announce the integration of the CADScor System at Connected Cardiovascular Care Associates' Texas facility," stated Acarix President & CEO Aamir Mahmood. "C3's dedication to providing accessible, top-tier care through innovative technology aligns seamlessly with the CADScor System's capability to deliver immediate, point-of-care results. This partnership enhances our ability to support physicians in making well-informed decisions for their patients."

### **For more information contact:**

Jennifer Monies, phone +1 (405) 550-8144, [jmonies@saxum.com](mailto:jmonies@saxum.com)

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com)

### **Attachments**

[Nationally Recognized Cardiology Practice Places Multiunit Order of the Acarix CADScor System](#)